Nathan Barnett R
Department of Neurology, University of Virginia, Charlottesville, VA 22908, USA.
Neurocrit Care. 2007;6(1):72-8. doi: 10.1385/NCC:6:1:72.
Hyponatremia, defined as a serum sodium concentration ([Na+]) less than 135 mEq/L, is commonly caused by elevated levels of the hormone arginine vasopressin (AVP), which causes water retention. The principal organ affected by disease-related morbidity is the brain. The neurologic complications associated with hyponatremia are attributable to cerebral edema and increased intracranial pressure, caused by the osmotically driven movement of water from the extracellular compartment into brain cells. Although neurologic symptoms induced by hyponatremia are limited by an adaptive brain mechanism known as "regulatory volume decrease," an overly rapid correction of serum [Na+] before the reversal of this adaptive response can also produce neurologic damage. The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) is a frequent cause of hyponatremia related to central nervous system disorders, neurosurgery, or the use of psychoactive drugs. Fluid restriction is the standard of care for patients with SIADH who are asymptomatic or who have only mild symptoms, but patients with severe or symptomatic hyponatremia require more aggressive therapy. Infusion of hypertonic saline is the usual approach to the treatment of symptomatic hyponatremia, but patients require frequent monitoring. Pharmacologic agents such as demeclocycline and lithium may be effective in some patients but are associated with undesirable adverse events. The AVPreceptor antagonists are a new therapeutic class for the treatment of hyponatremia. The first agent in this class approved for the treatment of euvolemic hyponatremia in hospitalized patients is conivaptan. Two other agents, tolvaptan and lixivaptan, are being evaluated in patients with euvolemic and hypervolemic hyponatremia. The AVP-receptor antagonists block the effects of elevated AVP and promote aquaresis, the electrolyte-sparing excretion of water, resulting in the correction of serum [Na+]. These agents may also have intrinsic neuroprotective effects.
低钠血症定义为血清钠浓度([Na+])低于135 mEq/L,通常由精氨酸加压素(AVP)水平升高引起,AVP会导致水潴留。受疾病相关发病率影响的主要器官是大脑。与低钠血症相关的神经并发症归因于脑水肿和颅内压升高,这是由水从细胞外间隙向脑细胞的渗透驱动运动引起的。尽管低钠血症引起的神经症状受到一种称为“调节性容积减少”的适应性脑机制的限制,但在这种适应性反应逆转之前血清[Na+]的过度快速纠正也会导致神经损伤。抗利尿激素不适当分泌综合征(SIADH)是与中枢神经系统疾病、神经外科手术或使用精神活性药物相关的低钠血症的常见原因。对于无症状或仅有轻微症状的SIADH患者,限液是标准治疗方法,但重度或有症状的低钠血症患者需要更积极的治疗。输注高渗盐水是治疗有症状低钠血症的常用方法,但患者需要频繁监测。地美环素和锂等药物在一些患者中可能有效,但会伴有不良事件。AVP受体拮抗剂是治疗低钠血症的一类新的治疗药物。该类中首个被批准用于治疗住院患者等渗性低钠血症的药物是考尼伐坦。另外两种药物托伐普坦和利昔伐坦正在等渗性和高渗性低钠血症患者中进行评估。AVP受体拮抗剂可阻断升高的AVP的作用并促进利水,即不伴有电解质丢失的水排泄,从而纠正血清[Na+]。这些药物可能还具有内在的神经保护作用。